Biosimilars at an inflection point: How regulatory reform, a maturing patent framework and a looming patent cliff are reshaping M&A Biosimilars at an inflection point: How regulatory reform, a maturing patent framework and a looming patent cliff are reshaping M&A by Samuel Cammer, Leslie Demers, and Rachel Turow at Skadden Read the update September 30, 2026 Morning Brief